Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorVanderbilt University Medical Center

About this trial

The goal of this observational study is to determine if electrophysiologic mapping and cardiac MRI can help identify patients that have genetic forms of cardiomyopathy that are at high risk for development of dangerous ventricular arrhythmias.

The investigators aim to study:

1. the prevalence and mechanism of inducible ventricular tachycardia 2. pace-mapping to define the site of origin of ventricular arrhythmias 3. voltage mapping to define low voltage scar substrate in the basal LV to determine the risk of development of ventricular arrhythmias in patients with genetic forms of cardiomyopathy.

Participants will undergo cardiac MRI before their scheduled procedure and voltage mapping during their scheduled procedure as part of data collection.

Eligibility criteria

Qualifiers

Adults aged 18 and older

Diagnosed with AF, frequent PVCs, or VT before age 60

Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation

Able to provide written, informed consent

Disqualifiers

Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure

VUS in 'possibly pathogenic' subgroup (control group only)

Previous PVC or VT ablation

LVEF <20%

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

200 Participants
are grouped into 3 trial groups